WO1995011004A1 - A personal care composition - Google Patents

A personal care composition Download PDF

Info

Publication number
WO1995011004A1
WO1995011004A1 PCT/EP1994/003432 EP9403432W WO9511004A1 WO 1995011004 A1 WO1995011004 A1 WO 1995011004A1 EP 9403432 W EP9403432 W EP 9403432W WO 9511004 A1 WO9511004 A1 WO 9511004A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
formula
carbon atoms
group
accordance
Prior art date
Application number
PCT/EP1994/003432
Other languages
French (fr)
Inventor
Lars Persson
Hazel Pool
Original Assignee
Berol Nobel Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berol Nobel Ab filed Critical Berol Nobel Ab
Priority to EP94930961A priority Critical patent/EP0737061A1/en
Priority to JP7511325A priority patent/JPH09504017A/en
Publication of WO1995011004A1 publication Critical patent/WO1995011004A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/442Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/45Derivatives containing from 2 to 10 oxyalkylene groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/463Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/10Washing or bathing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59Mixtures
    • A61K2800/596Mixtures of surface active compounds

Definitions

  • the present invention relates to a personal care composition in liquid or gel form suitable for use as a shower product.
  • the composition of the invention imparts an excellent skin feel.
  • personal care products like shower creams and shower gels, besides a cleaning effect, also provide a mild and silky feel to the skin both at the time of appli- cation and after the use.
  • the products shall also provide a foam of high volume and good texture to facilitate the appli ⁇ cation of the product on the skin e.g. by a sponge.
  • clea- ning products for personal care that contain an anionic surfactant and a betaine.
  • the betaines may cause irritation in the eyes and have a low contribution to a mild silky skin feel.
  • a skin cleaning mousse-forming product is also described in EP-B1-194 097.
  • the product contains a nonsoap surfactant such as a sulfonate, a sulfate or a betaine, and a moisturizer.
  • a specific skin feel aid is added.
  • One object of the present invention is to provide a mild personal care product with a smooth and silky feel at the time of application as well as after the use. Furthermore the level of foam volume shall be high. Another object is to obtain acceptable skin feel and foaming properties without the need of using amphoteric quarternized ammonium compounds, like betaines, and skin feel aids.
  • a personal care composition comprising a) a combination of amphoteric compounds containing i) at least one amphoteric compound, which has the formula R ⁇ (CO) n -[N-(CH 2 ) x ] y -N-Q (I) B B wherein R x is a hydrocarbon group of from 15 to 22 carbon atoms, n is 0 or 1, x is 2 or 3, y is an integer of 0 to 4, Q is CH 2 COOM or CH 2 CH 2 COOM, wherein M is hy ⁇ drogen or an ion from the groups of alkali metals, ammonium or substitued ammonium and B is hydrogen, an hydroxyalkyl group with 2-3 carbon atoms or a group Q as defined; ii) at least one amphoteric compound, which has the formula R 2 (CO) n -[N-(CH 2 ) x ] y -N-Q (II
  • the component a) is 10-35%, component b) 10-25% and component c) 50-80% by weight based on the total amount of a) , b) and c) .
  • the weight ratio between component a) and component c) is suitably from 2:3 to 1:8 and the weight ratio between component b) and component c) is from 1:2 to 1:8.
  • the composition contain at least one alkoxylated amide with the formula (III) and at least one alkoxylated amide with the formula (IV) , the weight ratio between the compounds with formula III and the compounds with formula (IV) being from 1:6 to 6:1.
  • a blend of these surfactants enables the manufacture of shower products with outstanding performance, especially with regard to after-use skin feel. It is the surfactants alone ' which are responsible for the skin feel and there is no need to add polymeric material or other emollients in order to achieve an exceptional after-use feel.
  • the amphoteric compounds with the formulae (I) and (II) also contribute to the cleaning effect of the composition.
  • the compounds with formula (I) promote the feel of foam and the after-use feel, while compounds with formula (II) generally promote foaming.
  • the alkoxylated amides of formula (IV) increases the volume of foam, while the compounds of formula (III) have a thickening effect in combination with an improved after-use feel and a creamy texture of the foam.
  • any expected toxic effects or skin irritaitons due to the presence of the anionic surfactant are essentially lowered depending on the substantial amounts of amphoteric compounds and alkoxylated amides in the composition.
  • i and R 2 are preferably aliphatic groups, R x containing 16-20, mainly 18 carbon atoms and R 2 10-14, mainly 12 carbon atoms.
  • the groups R ⁇ and R 2 can be both unsaturated and saturated and suitably they are derived from rapeseed oil and coconut oil.
  • One class of preferred ampholytic compounds with formu ⁇ lae (I) and (II) are those where x is 3, n is 0, y is 2-3 and B is the group Q.
  • Another class of suitable amphoteric compounds with formulae (I) and (II) are those where n is 1, and each B independently of each other hydrogen, a hydroxyalkyl group with 2-3 carbon atoms or the Q group with the proviso that at least one of the B groups is the hydroxyalkyl group. Examples of such compounds are those with the formulae R-C(O)-N-CH 2 CH 2 -N-CH 2 COOM (V) CH 2 CH 2 OH CH 2 COOM and
  • composition may also contain other types of amphoteric compounds as well as zwitterionic compounds like betaines.
  • Suitable zwitterionic compounds are those with the formula CH 3 R a -N + -(CH 2 ) m COOM (V) CH 3 wherein R a is a hydrocarbyl chain of 7-21 carbon atoms and preferably is an alkyl or alkenyl radical of from 11 to 17 carbon atoms; m is 1 or 2; M is preferably H or sodium ion.
  • Preferred alkoxylated amides with the formulae (III) and (IV) are those, where n is a number from 0 to 4, most preferably from 2-3, and R 3 is an acyl group with 16-20, mainly 18 carbon atoms and R- is an acyl group with 10-14, mainly 12 carbon atoms.
  • Preferably at least 50 % of all A groups are the ethyleneoxy group, and most preferably both R 5 and A are ethyleneoxy groups.
  • the R 3 and R 4 groups are suitably derived from rapeseed oil and coconut oil.
  • Anionic surfactants suitable for inclusion in the com- positions are those generally used in personal care products and include alkylsulfates, ethoxylated alkyl sulfates, alkyl polyglucoside sulfates, fatty acid polyglyceride sulfates, fatty acylamido polyoxyethylene sulfate, alkyl glyceryl ether sulfonates, methyl acyl taurates, fatty acyl glycinates, N-acyl glutamates, acyl isethionates, alkyl sulfosuccinates, alpha- sulfonated fatty acids, their salts and/or their esters, alkyl phosphate esters, ethoxylated alkyl phosphate esters, acyl sarcosinates and fatty acid/protein condensates, and mixtures thereof.
  • the alkyl and/or acyl groups for these surfactants contain 8-22,
  • the sulfate compounds especially the salts of sulfuric acid esters of the reaction product of 1 mole of a higher fatty alcohol with 10-18 carbon atoms and from about 1 to about 5 moles of ethylene oxide, with sodium, ammonium or magnesium being the preferred counterions.
  • Particu- lary preferred are the alkyl ether sulfates containing from about 2 to 4 moles of ethylene oxide, such as sodium lauryl dioxyethylene sulfate, sodium lauryl trioxyethylene sulfate.
  • the composition of the invention may also contain normally used components, such as preservatives, pearlescent agents, opacifiers, colourants and fragrance. Preservatives may e.g.
  • the pearlescent agent may e.g. be Empicol XP40 (Albright & Wilson) .
  • Opacifiers may suitably be polymeric substances, such as copolymers of vinyl pyrrolidone and styrene.
  • the colourants may e.g. include FDC Yellow and FDC Orange 4.
  • the pH of the composition should be within a range of 4.5 to 7.0, and preferably 5.5.
  • a pH adjusting agent can be used, such as an organic acid, e.g. citric or lactic acid, or an inorganic acid, e.g. hydrochloric acid.
  • compositions were prepared from an anionic surfactant, amphoteric surfactants and amide etoxylates.
  • the compounds used are as set forth in the following table.
  • R ⁇ is a C 16 _ 18 aliphatic group, x and y is 3, n is 0, and B and Q are
  • a quantity of 0.5 g of the formulations was transferred to the arm, and the arm was then rubbed five times initially, and then up to a further twenty times. Each time the volume of foam and the feel of the foam on the skin were recorded.
  • the arms were then rinsed with warm water and dried using a clean towel.
  • the after-feel was recorded after five minutes. The following results were obtained.
  • formulation 3, 6 and 7 in accordance with the invention exhibits advantageous and synergistic effects in comparison with the formulations 1, 2, 4 and 5.
  • a shower cream composition based on formulation 7 was compared with three shower products on the commercial market with regard to the volume of foam, feel of foam and after-use feel.
  • composition of the shower cream was as follows.
  • the pH-value of the shower cream was adjusted to 5.3 by adding citric acid. After this addition the shower cream had an viscosity of 16 000 cps.

Abstract

The invention relates to a personal care composition in liquid or gel form for use as a shower product. The composition which contains two amphoteric compounds with hydrocarbon groups of different sizes, an ethoxylated amide and a water-soluble anionic surfactant, imparts an excellent mild and silky feel to the skin.

Description

A PERSONAL CARE COMPOSITION
The present invention relates to a personal care composition in liquid or gel form suitable for use as a shower product. The composition of the invention imparts an excellent skin feel.
It is desired that personal care products, like shower creams and shower gels, besides a cleaning effect, also provide a mild and silky feel to the skin both at the time of appli- cation and after the use. The products shall also provide a foam of high volume and good texture to facilitate the appli¬ cation of the product on the skin e.g. by a sponge.
In the prior art a number of a personal care products is known. For examples, in EP-A1-523 127 and EP-A1-417 501, clea- ning products for personal care are disclosed, that contain an anionic surfactant and a betaine. However, the betaines may cause irritation in the eyes and have a low contribution to a mild silky skin feel. A skin cleaning mousse-forming product is also described in EP-B1-194 097. The product contains a nonsoap surfactant such as a sulfonate, a sulfate or a betaine, and a moisturizer. In order to obtain an acceptable skin feel a specific skin feel aid is added.
One object of the present invention is to provide a mild personal care product with a smooth and silky feel at the time of application as well as after the use. Furthermore the level of foam volume shall be high. Another object is to obtain acceptable skin feel and foaming properties without the need of using amphoteric quarternized ammonium compounds, like betaines, and skin feel aids. According to the present invention it has been found that these objects may be met by a personal care composition comprising a) a combination of amphoteric compounds containing i) at least one amphoteric compound, which has the formula Rι(CO)n-[N-(CH2)x]y-N-Q (I) B B wherein Rx is a hydrocarbon group of from 15 to 22 carbon atoms, n is 0 or 1, x is 2 or 3, y is an integer of 0 to 4, Q is CH2COOM or CH2CH2COOM, wherein M is hy¬ drogen or an ion from the groups of alkali metals, ammonium or substitued ammonium and B is hydrogen, an hydroxyalkyl group with 2-3 carbon atoms or a group Q as defined; ii) at least one amphoteric compound, which has the formula R2(CO)n-[N-(CH2)x]y-N-Q (II) B B wherein R2 is a hydrocarbon group of from 7 to 14 carbon atoms, and n, x, y, Q and B have the same meanings as in formula (I) , the weight ratio between the amphoteric compounds with formula (I) and the amphoteric compounds with formula (II) being 1:3-6:1, b) at least one alkoxylated amide, which has the formula R3NHR5(A)nH (HI) wherein R3 is an acyl group with 15-22 carbon atoms, R5 is an alkylene oxy group with 2-4 carbon atoms, A is an alkyleneoxy group with 2-3 carbon atoms and n is a number from 0 to 6, or at least one alkoxylated amide, which has the formula
R4NHR5(A)nH (IV) wherein R4 is an acyl group with 7-14 carbon atoms and R5, A and n have the same meanings as in formula (III) , or a combination thereof, and c) a water soluble anionic surface active agent, the amounts of component a) , b) and c) being 5-50%, 5-40% and 45-90%, based on the total weight of a) , b) and c) respec¬ tively, and the total amount of a) , b) and c) being 1-100% based on the total weight of the composition. Preferably, the component a) is 10-35%, component b) 10-25% and component c) 50-80% by weight based on the total amount of a) , b) and c) . The weight ratio between component a) and component c) is suitably from 2:3 to 1:8 and the weight ratio between component b) and component c) is from 1:2 to 1:8. In a preferred em- bodyment the composition contain at least one alkoxylated amide with the formula (III) and at least one alkoxylated amide with the formula (IV) , the weight ratio between the compounds with formula III and the compounds with formula (IV) being from 1:6 to 6:1. By combining the compounds of the present composition in the specified amount stated above, it is possible to obtain synergistic properties which make the composition extremely suitable to be used in personal care products, such as shower gels and shower creams.
A blend of these surfactants enables the manufacture of shower products with outstanding performance, especially with regard to after-use skin feel. It is the surfactants alone ' which are responsible for the skin feel and there is no need to add polymeric material or other emollients in order to achieve an exceptional after-use feel.
Besides the anionic surfactant, the amphoteric compounds with the formulae (I) and (II) also contribute to the cleaning effect of the composition. In addition, the compounds with formula (I) promote the feel of foam and the after-use feel, while compounds with formula (II) generally promote foaming. The alkoxylated amides of formula (IV) increases the volume of foam, while the compounds of formula (III) have a thickening effect in combination with an improved after-use feel and a creamy texture of the foam. Furthermore, any expected toxic effects or skin irritaitons due to the presence of the anionic surfactant are essentially lowered depending on the substantial amounts of amphoteric compounds and alkoxylated amides in the composition.
In"the formulae (I) and (II), i and R2 are preferably aliphatic groups, Rx containing 16-20, mainly 18 carbon atoms and R2 10-14, mainly 12 carbon atoms. The groups R} and R2 can be both unsaturated and saturated and suitably they are derived from rapeseed oil and coconut oil.
One class of preferred ampholytic compounds with formu¬ lae (I) and (II) are those where x is 3, n is 0, y is 2-3 and B is the group Q. Another class of suitable amphoteric compounds with formulae (I) and (II) are those where n is 1, and each B independently of each other hydrogen, a hydroxyalkyl group with 2-3 carbon atoms or the Q group with the proviso that at least one of the B groups is the hydroxyalkyl group. Examples of such compounds are those with the formulae R-C(O)-N-CH2CH2-N-CH2COOM (V) CH2CH2OH CH2COOM and
R-C(0)-N-CH2CH2-N-CH2COOM (VI) H CH2CH2OH where M has the same meaning as mentioned above and R is R: or R2 where Rλ and R2 have the same meanings as mentioned above. In addition to the amphoteric surfactants of formulae (I) and (II) the composition may also contain other types of amphoteric compounds as well as zwitterionic compounds like betaines. Examples of suitable zwitterionic compounds are those with the formula CH3 Ra-N+-(CH2)mCOOM (V) CH3 wherein Ra is a hydrocarbyl chain of 7-21 carbon atoms and preferably is an alkyl or alkenyl radical of from 11 to 17 carbon atoms; m is 1 or 2; M is preferably H or sodium ion. Preferred alkoxylated amides with the formulae (III) and (IV) are those, where n is a number from 0 to 4, most preferably from 2-3, and R3 is an acyl group with 16-20, mainly 18 carbon atoms and R- is an acyl group with 10-14, mainly 12 carbon atoms. Preferably at least 50 % of all A groups are the ethyleneoxy group, and most preferably both R5 and A are ethyleneoxy groups. The R3 and R4 groups are suitably derived from rapeseed oil and coconut oil.
Anionic surfactants suitable for inclusion in the com- positions are those generally used in personal care products and include alkylsulfates, ethoxylated alkyl sulfates, alkyl polyglucoside sulfates, fatty acid polyglyceride sulfates, fatty acylamido polyoxyethylene sulfate, alkyl glyceryl ether sulfonates, methyl acyl taurates, fatty acyl glycinates, N-acyl glutamates, acyl isethionates, alkyl sulfosuccinates, alpha- sulfonated fatty acids, their salts and/or their esters, alkyl phosphate esters, ethoxylated alkyl phosphate esters, acyl sarcosinates and fatty acid/protein condensates, and mixtures thereof. The alkyl and/or acyl groups for these surfactants contain 8-22, preferably 10-18 carbon atoms.
Preferred from the viewpoint of optimum characteristics for shower products are the sulfate compounds, especially the salts of sulfuric acid esters of the reaction product of 1 mole of a higher fatty alcohol with 10-18 carbon atoms and from about 1 to about 5 moles of ethylene oxide, with sodium, ammonium or magnesium being the preferred counterions. Particu- lary preferred are the alkyl ether sulfates containing from about 2 to 4 moles of ethylene oxide, such as sodium lauryl dioxyethylene sulfate, sodium lauryl trioxyethylene sulfate. In addition to the above components the composition of the invention may also contain normally used components, such as preservatives, pearlescent agents, opacifiers, colourants and fragrance. Preservatives may e.g. include Euxyl K 100 (Sch lke and Mayr), benzyl alcohol, metylchloroisothiazolinone and methylisothiazolinone. The pearlescent agent may e.g. be Empicol XP40 (Albright & Wilson) . Opacifiers may suitably be polymeric substances, such as copolymers of vinyl pyrrolidone and styrene. The colourants may e.g. include FDC Yellow and FDC Orange 4.
The pH of the composition should be within a range of 4.5 to 7.0, and preferably 5.5. A pH adjusting agent can be used, such as an organic acid, e.g. citric or lactic acid, or an inorganic acid, e.g. hydrochloric acid.
The invention is further ilustrated by means of the following examples.
Example 1
A number of compositions were prepared from an anionic surfactant, amphoteric surfactants and amide etoxylates. The compounds used are as set forth in the following table.
Table 1
Compound nr Chemical structure
A Formula I, where Rλ is a C16_18 aliphatic group, x and y is 3, n is 0, and B and Q are
C2H4COONa
B Formula II, where R2 is a C12_ι aliphatic group, x is 3, y is 2, n is 0, and B and Q are
C2H4COONa
C Formula III, where R3 is a C16_18 aliphatic group; R5=A=C2H40; and n=2
D Formula IV, where R4 is an C12_14 aliphatic group; R5=A=C2H40; and n=2
E Lauryl di(oxyethylene)sulphate
By using these surfactant A-E the following compositions were formulated.
Table 2
Formulation Ingredient % by weight
1 B 3
C 2
E 15
2 A 3
C 2
E 15
3 A 1.5
B 1.5
C 2
E 15
4 B 3
D 4
E 15
5 A 3
D 3
E 15
6 A 1.5
B 1.5
D 3
E 15
7 A 1.5
B 1.5
C 2
D 3
E 15
The seven formulations were evaluated with regard to volume of foam, feel of foam on application and the after-use feel of skin. These parameters were in accordance with scales from 0 to 100 having the following meanings. Volume of foam 0 = None 100 = Copious
Feel of foam 0 = Unacceptable 100 = Extremely rich
After-use feel 0 = Unacceptable 100 = Excellent
The assessments were carried out on the forearms, which were prewashed with mild Palmolive soap, and wetted with warm water, before applying the test formulations.
A quantity of 0.5 g of the formulations was transferred to the arm, and the arm was then rubbed five times initially, and then up to a further twenty times. Each time the volume of foam and the feel of the foam on the skin were recorded.
The arms were then rinsed with warm water and dried using a clean towel. The after-feel was recorded after five minutes. The following results were obtained.
Formulation Foam Volume Feel of foam After-use feel
1 67.5 67.5 82.5
2 67.5 67.5 82.5
3 70 72.5 82.5
4 67.5 67.5 72.5
5 70 72.5 77.5
6 75 72.5 77.5
7 75 72.5 85
From the results it is evident that formulation 3, 6 and 7 in accordance with the invention exhibits advantageous and synergistic effects in comparison with the formulations 1, 2, 4 and 5.
Example 2
A shower cream composition based on formulation 7 was compared with three shower products on the commercial market with regard to the volume of foam, feel of foam and after-use feel.
The composition of the shower cream was as follows.
Components % by weight
A 1.5
B 1.5
C 2.0
D 3.0
E 15
Vinyl pyrrolidone/styren copolymer (Antara
430) 1.5
Propylenglycol 2.0
Preservative (Euxyl K 100) 0.1
Perfume (Frequent K/25952) 0.3
Water up to 100 %
The pH-value of the shower cream was adjusted to 5.3 by adding citric acid. After this addition the shower cream had an viscosity of 16 000 cps.
The following results were obtained.
Product Foam Volume Feel of foam After-use feel
Shower cream of the invention 75 72.5 85
Comparison 1 75 70 82.5
Comparison 2 70 70 67.5
Comparison 3 75 75 80
From the results it is evident that the shower cream product in accordance with the invention gives an exceptional after-use feel without the need of vegetable oils or synthetic emollient materials. Example 3
The following formulations were prepared.
Components Formulation, % by weight
8 9 10
A - 1.5 1.5
A' 1.5 - -
B 1.5 1.5 -
B' - - 1.5
C 2.0 - 2.0
C« - 2.0 -
D 3.0 - 3.0
D1 - 3.0 -
E 15.0 15.0 15.0
A1 = Formula (I), where Rx(CO)n=C16_18 acyl group; x=2; y=3; B=Q=CH2COONa
B' = Mixture of Formula (V) and (VII), where R(CO)=C12_14 acyl C = Formula (III) , where R3=C16_ aliphatic group; R5=C2H40; A=C2H40; and n=3
D' = Formula (III) , where R3-=C12_14 aliphatic group; R5=C2H40; and n=0
Compounds A, B, C, D and E were the same as in Example 1. The formulations 8, 9 and 10 were then tested in the same manner as in Example 1. The same results as for formulation 7 in Example 1 were obtained, but with the exception that Feel of Foam for formulations 8 and 9 was 75. The formulation 9 had also a slightly higher viscosity than formulations 7, 8 and 10.

Claims

1. A personal care composition comprising a) a combination of amphoteric compounds containing i) at least one amphoteric compound, which has the formula Rι(CO)n-[^-(CH2)x]y-N-Q (I)
B B wherein Rx is a hydrocarbon group of from 15 to 22 carbon atoms, n is 0 or 1, x is 2 or 3, y is an integer of 0 to 4, Q is CH2COOM or CH2CH2COOM, wherein M is hy- drogen or an ion from the groups of alkali metals, ammonium or substitued ammonium and B is hydrogen, an hydroxyalkyl group with 2-3 carbon atoms or a group Q as defined; ii) at least one amphoteric compound, which has the formula R2(CO)n-[N-(CH2)x]y-N-Q (II)
B B wherein R2 is a hydrocarbon group of from 7 to 14 carbon atoms, and n, x, y, Q and B have the same meanings as in formula (I) , the weight ratio between the amphoteric compounds with formula (I) and the amphoteric compounds with formula (II) being 1:3-6:1, b) at least one alkoxylated amide, which has the formula
R3NHR5(A)nH (III) wherein R3 is an acyl group with 15-22 carbon atoms, R5 is an alkylene oxy group with 2-4 carbon atoms, A is an alkyleneoxy group with 2-3 carbon atoms and n is a number from 0 to 6, or at least one alkoxylated amide, which has the formula
R4NHR5 (A) nH ( IV) wherein R4 is an acyl group with 7-14 carbon atoms and
R5, A and n have the same meanings as in formula (III), or a combination thereof, and c) a water soluble anionic surface active agent, the amounts of component a) , b) and c) being 5-50%, 5-40% and 45-90%, based on the total amount of a), b) and c) respec¬ tively, and the total amount of a) , b) and c) being 1-100% based on the total amount of the composition.
2. A composition in accordance with claim 1, characterized in that in formulae (I) and (II) Rλ is an aliphatic group with 16-20 carbon atoms and R2 is an aliphatic group with 10-14 carbon atoms.
3. A composition in accordance with claim 2, characterized in that n is 1.
4. A composition in accordance with claim 1 or 2, characterized in that x is 3, n is 0 and B is the group Q.
5. A composition in accordance with any one of claims 1-4, characterized in that it contains at least one compound with the formula (III) and at least one compound with the formula (IV) in a weight ratio of 1:6 to 6:1.
6. A composition in accordance with any one of claims 1-5, characterized in that in formulae (III) and (IV) R3 is an ali- phatic group with 16-20 carbon atoms and R4 is an aliphatic group with 10-14 carbon atoms.
7. A composition in accordance with claim 6, characterized in that R5 and A are ethyleneoxy groups.
8. A composition in accordance with any one of claims 1-7, characterized in that the anionic surfactant is a sulphate or sulphonate.
9. A composition in accordance with claim 8, characterized in that the anionic surfactant is a salt of sulfuric ester of the reaction product of 1 mole of a fatty alcohol and from 1 to 5 moles of ethylene oxide.
10. A composition in accordance with any one of claims 1-9, characterized in that the component a) is 10-35 %, component b) 10-25 %, and component c) 50-80 %, based on the total weight of components a) , b) , and c) .
11. Use of a composition in accordance with any one of claims 1-10 in the formulation of a shower product.
PCT/EP1994/003432 1993-10-22 1994-10-17 A personal care composition WO1995011004A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP94930961A EP0737061A1 (en) 1993-10-22 1994-10-17 A personal care composition
JP7511325A JPH09504017A (en) 1993-10-22 1994-10-17 Personal care composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9303481A SE9303481L (en) 1993-10-22 1993-10-22 hygiene composition
SE9303481-7 1993-10-22

Publications (1)

Publication Number Publication Date
WO1995011004A1 true WO1995011004A1 (en) 1995-04-27

Family

ID=20391505

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/003432 WO1995011004A1 (en) 1993-10-22 1994-10-17 A personal care composition

Country Status (4)

Country Link
EP (1) EP0737061A1 (en)
JP (1) JPH09504017A (en)
SE (1) SE9303481L (en)
WO (1) WO1995011004A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801139A (en) * 1997-06-05 1998-09-01 Lever Brothers Company, Division Of Conopco, Inc. Process for making bar compositions comprising novel chelating surfactants
US5869441A (en) * 1997-06-05 1999-02-09 Lever Brothers Company, Division Of Conopco, Inc. Bar compositions comprising novel chelating surfactants
DE10150410A1 (en) * 2001-08-10 2003-02-27 Beiersdorf Ag Cosmetic cleaning preparations based on a combination of sodium laureth sulfate and alkyl polyamphopolycarboxylglycinates
US8450298B2 (en) 2008-11-07 2013-05-28 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US9006487B2 (en) 2005-06-15 2015-04-14 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
US9181321B2 (en) 2013-03-14 2015-11-10 Shire Human Genetic Therapies, Inc. CFTR mRNA compositions and related methods and uses
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
US9227917B2 (en) 2012-08-13 2016-01-05 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
US9308281B2 (en) 2011-06-08 2016-04-12 Shire Human Genetic Therapies, Inc. MRNA therapy for Fabry disease
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
US9522176B2 (en) 2013-10-22 2016-12-20 Shire Human Genetic Therapies, Inc. MRNA therapy for phenylketonuria
US9629804B2 (en) 2013-10-22 2017-04-25 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger RNA
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
US9850269B2 (en) 2014-04-25 2017-12-26 Translate Bio, Inc. Methods for purification of messenger RNA
US9957499B2 (en) 2013-03-14 2018-05-01 Translate Bio, Inc. Methods for purification of messenger RNA
US10022455B2 (en) 2014-05-30 2018-07-17 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10138213B2 (en) 2014-06-24 2018-11-27 Translate Bio, Inc. Stereochemically enriched compositions for delivery of nucleic acids
US10576166B2 (en) 2009-12-01 2020-03-03 Translate Bio, Inc. Liver specific delivery of messenger RNA
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
US11173190B2 (en) 2017-05-16 2021-11-16 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR
US11224642B2 (en) 2013-10-22 2022-01-18 Translate Bio, Inc. MRNA therapy for argininosuccinate synthetase deficiency
US11253605B2 (en) 2017-02-27 2022-02-22 Translate Bio, Inc. Codon-optimized CFTR MRNA
US11254936B2 (en) 2012-06-08 2022-02-22 Translate Bio, Inc. Nuclease resistant polynucleotides and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127580A2 (en) * 1983-05-31 1984-12-05 Ciba-Geigy Ag Mixtures of quaternary polymeric ammonium salts and of a ternary surfactant system based on non ionic, anionic and amphoteric surfactants, its preparation and its use in cosmetic compositions
EP0160507A2 (en) * 1984-04-25 1985-11-06 Eric Graham Fishlock-Lomax Shampoo compositions
WO1992004882A1 (en) * 1990-09-21 1992-04-02 The Procter & Gamble Company Mild shampoo compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0127580A2 (en) * 1983-05-31 1984-12-05 Ciba-Geigy Ag Mixtures of quaternary polymeric ammonium salts and of a ternary surfactant system based on non ionic, anionic and amphoteric surfactants, its preparation and its use in cosmetic compositions
EP0160507A2 (en) * 1984-04-25 1985-11-06 Eric Graham Fishlock-Lomax Shampoo compositions
WO1992004882A1 (en) * 1990-09-21 1992-04-02 The Procter & Gamble Company Mild shampoo compositions

Cited By (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869441A (en) * 1997-06-05 1999-02-09 Lever Brothers Company, Division Of Conopco, Inc. Bar compositions comprising novel chelating surfactants
US5801139A (en) * 1997-06-05 1998-09-01 Lever Brothers Company, Division Of Conopco, Inc. Process for making bar compositions comprising novel chelating surfactants
DE10150410A1 (en) * 2001-08-10 2003-02-27 Beiersdorf Ag Cosmetic cleaning preparations based on a combination of sodium laureth sulfate and alkyl polyamphopolycarboxylglycinates
US9006487B2 (en) 2005-06-15 2015-04-14 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
US10844028B2 (en) 2008-11-07 2020-11-24 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US8969353B2 (en) 2008-11-07 2015-03-03 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US8450298B2 (en) 2008-11-07 2013-05-28 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US11414393B2 (en) 2008-11-07 2022-08-16 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US10189802B2 (en) 2008-11-07 2019-01-29 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US9556110B2 (en) 2008-11-07 2017-01-31 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US10576166B2 (en) 2009-12-01 2020-03-03 Translate Bio, Inc. Liver specific delivery of messenger RNA
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
US10933139B2 (en) 2011-03-28 2021-03-02 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
US10117934B2 (en) 2011-03-28 2018-11-06 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
US11338044B2 (en) 2011-06-08 2022-05-24 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US10238754B2 (en) 2011-06-08 2019-03-26 Translate Bio, Inc. Lipid nanoparticle compositions and methods for MRNA delivery
US11052159B2 (en) 2011-06-08 2021-07-06 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11951181B2 (en) 2011-06-08 2024-04-09 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11951180B2 (en) 2011-06-08 2024-04-09 Translate Bio, Inc. Lipid nanoparticle compositions and methods for MRNA delivery
US10888626B2 (en) 2011-06-08 2021-01-12 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US10507249B2 (en) 2011-06-08 2019-12-17 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11730825B2 (en) 2011-06-08 2023-08-22 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11951179B2 (en) 2011-06-08 2024-04-09 Translate Bio, Inc. Lipid nanoparticle compositions and methods for MRNA delivery
US11185595B2 (en) 2011-06-08 2021-11-30 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11547764B2 (en) 2011-06-08 2023-01-10 Translate Bio, Inc. Lipid nanoparticle compositions and methods for MRNA delivery
US10413618B2 (en) 2011-06-08 2019-09-17 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US10350303B1 (en) 2011-06-08 2019-07-16 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US9597413B2 (en) 2011-06-08 2017-03-21 Shire Human Genetic Therapies, Inc. Pulmonary delivery of mRNA
US11291734B2 (en) 2011-06-08 2022-04-05 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US9308281B2 (en) 2011-06-08 2016-04-12 Shire Human Genetic Therapies, Inc. MRNA therapy for Fabry disease
US11254936B2 (en) 2012-06-08 2022-02-22 Translate Bio, Inc. Nuclease resistant polynucleotides and uses thereof
US9439968B2 (en) 2012-08-13 2016-09-13 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US9227917B2 (en) 2012-08-13 2016-01-05 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
US11510937B2 (en) 2013-03-14 2022-11-29 Translate Bio, Inc. CFTR MRNA compositions and related methods and uses
US10420791B2 (en) 2013-03-14 2019-09-24 Translate Bio, Inc. CFTR MRNA compositions and related methods and uses
US11692189B2 (en) 2013-03-14 2023-07-04 Translate Bio, Inc. Methods for purification of messenger RNA
US11820977B2 (en) 2013-03-14 2023-11-21 Translate Bio, Inc. Methods for purification of messenger RNA
US9181321B2 (en) 2013-03-14 2015-11-10 Shire Human Genetic Therapies, Inc. CFTR mRNA compositions and related methods and uses
US10876104B2 (en) 2013-03-14 2020-12-29 Translate Bio, Inc. Methods for purification of messenger RNA
US9957499B2 (en) 2013-03-14 2018-05-01 Translate Bio, Inc. Methods for purification of messenger RNA
US9713626B2 (en) 2013-03-14 2017-07-25 Rana Therapeutics, Inc. CFTR mRNA compositions and related methods and uses
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
US9629804B2 (en) 2013-10-22 2017-04-25 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger RNA
US10052284B2 (en) 2013-10-22 2018-08-21 Translate Bio, Inc. Lipid formulations for delivery of messenger RNA
US9522176B2 (en) 2013-10-22 2016-12-20 Shire Human Genetic Therapies, Inc. MRNA therapy for phenylketonuria
US11890377B2 (en) 2013-10-22 2024-02-06 Translate Bio, Inc. Lipid formulations for delivery of messenger RNA
US10959953B2 (en) 2013-10-22 2021-03-30 Translate Bio, Inc. Lipid formulations for delivery of messenger RNA
US10208295B2 (en) 2013-10-22 2019-02-19 Translate Bio, Inc. MRNA therapy for phenylketonuria
US11377642B2 (en) 2013-10-22 2022-07-05 Translate Bio, Inc. mRNA therapy for phenylketonuria
US10493031B2 (en) 2013-10-22 2019-12-03 Translate Bio, Inc. Lipid formulations for delivery of messenger RNA
US11224642B2 (en) 2013-10-22 2022-01-18 Translate Bio, Inc. MRNA therapy for argininosuccinate synthetase deficiency
US11884692B2 (en) 2014-04-25 2024-01-30 Translate Bio, Inc. Methods for purification of messenger RNA
US11059841B2 (en) 2014-04-25 2021-07-13 Translate Bio, Inc. Methods for purification of messenger RNA
US10155785B2 (en) 2014-04-25 2018-12-18 Translate Bio, Inc. Methods for purification of messenger RNA
US9850269B2 (en) 2014-04-25 2017-12-26 Translate Bio, Inc. Methods for purification of messenger RNA
US10286083B2 (en) 2014-05-30 2019-05-14 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10493166B2 (en) 2014-05-30 2019-12-03 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US11433144B2 (en) 2014-05-30 2022-09-06 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10293057B2 (en) 2014-05-30 2019-05-21 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10022455B2 (en) 2014-05-30 2018-07-17 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10286082B2 (en) 2014-05-30 2019-05-14 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10912844B2 (en) 2014-05-30 2021-02-09 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US11104652B2 (en) 2014-06-24 2021-08-31 Translate Bio, Inc. Stereochemically enriched compositions for delivery of nucleic acids
US10138213B2 (en) 2014-06-24 2018-11-27 Translate Bio, Inc. Stereochemically enriched compositions for delivery of nucleic acids
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
US11253605B2 (en) 2017-02-27 2022-02-22 Translate Bio, Inc. Codon-optimized CFTR MRNA
US11173190B2 (en) 2017-05-16 2021-11-16 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA

Also Published As

Publication number Publication date
EP0737061A1 (en) 1996-10-16
SE9303481D0 (en) 1993-10-22
SE9303481L (en) 1995-04-23
JPH09504017A (en) 1997-04-22

Similar Documents

Publication Publication Date Title
WO1995011004A1 (en) A personal care composition
FI81605C (en) SKUMBILDANDE EMULSIONSPRODUKT FOER HUDRENING.
US7749523B2 (en) Emollient skin conditioning cream and method
KR970001645B1 (en) Hair shampoo
US4867971A (en) Low pH shampoo containing climbazole
US5002680A (en) Mild skin cleansing aerosol mousse with skin feel and moisturization benefits
WO1996021424A2 (en) Mild cold pearlizing concentrates
JP2003246713A (en) Method for preparing normal-temperature pearlescentized concentrate
JPWO2006030990A1 (en) Cleaning composition
JPH01168612A (en) Liquid detergent composition
JPH11189788A (en) Transparent gel-like detergent composition
JPH01178596A (en) Detergent composition
CN100408019C (en) Abluent composition
JP4982018B2 (en) Cleaning composition
JPH01168613A (en) Detergent composition
JPH03255021A (en) Liquid skin cleaning agent composition
JPH04198125A (en) Detergent composition
WO1995001153A1 (en) Shampoo compositions
US20060018865A1 (en) Foaming cleansing composition
JP3130373B2 (en) Detergent composition
JPH05504576A (en) cosmetic cleansing agent
JPH0816240B2 (en) Liquid detergent composition having a pearl-like appearance
CA2022068A1 (en) Balanced neutral liquid detergent/lotion emulsion formulation
JPS59117598A (en) Creamy detergent
JPS5918440B2 (en) cleaning composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): FI JP NO US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: US

Ref document number: 1996 632462

Date of ref document: 19960419

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1994930961

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994930961

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994930961

Country of ref document: EP